Biotechnology company developing biologic therapeutics for oncology and orphan diseases.
Inhibrx, Inc., a clinical-stage biotechnology firm based in La Jolla, California, specializes in advancing a diverse pipeline of innovative biologic therapeutic candidates. Central to its portfolio is INBRX-109, a tetravalent agonist targeting death receptor 5, currently undergoing Phase 2 clinical trials for the treatment of cancers such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma. Complementing this, INBRX-105 represents another significant candidate a tetravalent conditional agonist of programmed death-ligand 1 (PD-L1) and a conditional agonist of 4-1BB currently in Phase 1 clinical trials for patients with locally advanced or metastatic solid tumors.
In addition to these pivotal candidates, Inhibrx, Inc. is advancing INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic, through Phase 1 clinical trials. This candidate aims to address AAT deficiency, a genetic disorder impacting lung and liver function. Furthermore, the company is developing INBRX-106, a hexavalent agonist targeting OX40, with potential applications across various oncology indications.
Founded in 2010, Inhibrx, Inc. has built a foundation grounded in cutting-edge research and development within the biotechnology sector. Headquartered in La Jolla, the company benefits from its strategic location within Southern California's biotech community, fostering collaboration and innovation with leading academic and research institutions.
With a commitment to pioneering biologic therapies and addressing significant medical challenges, Inhibrx, Inc. is poised to advance the forefront of therapeutic innovation. By harnessing the potential of its robust pipeline and leveraging strategic partnerships, the company aims to deliver transformative treatments that improve outcomes for patients worldwide.